Insulet Co. (NASDAQ:PODD) Receives $239.18 Consensus Target Price from Analysts

Shares of Insulet Co. (NASDAQ:PODD) have earned an average recommendation of “Moderate Buy” from the eighteen ratings firms that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating on the company. The average 1-year price target among analysts that have covered the stock in the last year is $239.18.

Several equities analysts have recently issued reports on the stock. Redburn Atlantic assumed coverage on shares of Insulet in a research note on Thursday, May 30th. They set a “buy” rating and a $235.00 price target for the company. Jefferies Financial Group upped their price target on Insulet from $255.00 to $260.00 and gave the company a “buy” rating in a research report on Friday, May 10th. Canaccord Genuity Group restated a “buy” rating and set a $234.00 price objective on shares of Insulet in a research report on Tuesday. Barclays reduced their target price on Insulet from $213.00 to $200.00 and set an “equal weight” rating on the stock in a report on Monday, May 13th. Finally, Wolfe Research upgraded shares of Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target for the company in a report on Tuesday, May 7th.

Insider Activity at Insulet

In other Insulet news, Director Timothy J. Scannell sold 3,300 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total value of $596,970.00. Following the transaction, the director now owns 42,586 shares in the company, valued at $7,703,807.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Timothy J. Scannell sold 3,300 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $180.90, for a total transaction of $596,970.00. Following the transaction, the director now directly owns 42,586 shares of the company’s stock, valued at $7,703,807.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mark N. Field sold 1,500 shares of Insulet stock in a transaction on Friday, June 14th. The shares were sold at an average price of $199.96, for a total transaction of $299,940.00. Following the completion of the sale, the senior vice president now directly owns 12,875 shares of the company’s stock, valued at approximately $2,574,485. The disclosure for this sale can be found here. Insiders sold 13,931 shares of company stock valued at $2,636,286 in the last three months. Corporate insiders own 0.47% of the company’s stock.

Hedge Funds Weigh In On Insulet

Several large investors have recently added to or reduced their stakes in the business. Capital Research Global Investors raised its stake in shares of Insulet by 19.7% in the fourth quarter. Capital Research Global Investors now owns 9,476,623 shares of the medical instruments supplier’s stock worth $2,056,255,000 after purchasing an additional 1,556,455 shares during the last quarter. Vanguard Group Inc. grew its holdings in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,199,114 shares of the medical instruments supplier’s stock worth $1,405,328,000 after buying an additional 169,506 shares in the last quarter. Baillie Gifford & Co. raised its position in Insulet by 30.8% in the 2nd quarter. Baillie Gifford & Co. now owns 1,886,062 shares of the medical instruments supplier’s stock valued at $380,607,000 after buying an additional 443,783 shares during the last quarter. Norges Bank bought a new position in Insulet during the 4th quarter valued at $227,655,000. Finally, William Blair Investment Management LLC grew its stake in shares of Insulet by 3.7% in the 1st quarter. William Blair Investment Management LLC now owns 952,268 shares of the medical instruments supplier’s stock worth $163,219,000 after acquiring an additional 33,579 shares in the last quarter.

Insulet Trading Up 1.3 %

NASDAQ PODD opened at $193.30 on Monday. Insulet has a twelve month low of $125.82 and a twelve month high of $283.00. The business’s fifty day moving average is $193.24 and its 200 day moving average is $184.74. The company has a quick ratio of 2.75, a current ratio of 3.74 and a debt-to-equity ratio of 1.72. The company has a market cap of $13.54 billion, a price-to-earnings ratio of 58.58, a price-to-earnings-growth ratio of 3.50 and a beta of 1.16.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.34. The firm had revenue of $441.70 million for the quarter, compared to analyst estimates of $424.05 million. Insulet had a return on equity of 34.06% and a net margin of 13.14%. The business’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same period last year, the firm posted $0.23 earnings per share. As a group, sell-side analysts expect that Insulet will post 3.11 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.